| SEC Form 4 |
|------------|
|------------|

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | | | | |
| Estimated average burden | | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | | |

| Check this box if no longer sub Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |
|---|--|
|---|--|

to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Addres <u>GRAF FINC</u> | 1 0 | Person [*] N FRIEDRICH | 2. Issuer Name and Ticker or Trading Symbol <u>IOVANCE BIOTHERAPEUTICS, INC.</u> [IOVA] | | tionship of Reporting Pe all applicable) Director Officer (give title | 10% Owner Other (specify | | | | | |
|-------------------------------------|--|------------------------------------|---|----------------------|--|-----------------------------|--|--|--|--|--|
| (Last) C/O IOVANCE | (First) BIOTHERA | (Middle) PEUTICS, INC. | 3. Date of Earliest Transaction (Month/Day/Year) 04/15/2024 | | below) Chief Medica | below) I Officer | | | | | |
| 825 INDUSTRIAL ROAD, 4TH FLOOR | | TH FLOOR | 4. If Amendment, Date of Original Filed (Month/Day/Year) | ng (Check Applicable | | | | | | | |
| (Street) | | | | | Form filed by One Re | , s | | | | | |
| SAN CARLOS | CA | 94070 | | | Form filed by More the Person | an One Reporting | | | | | |
| (City) | (State) | (Zip) | Rule 10b5-1(c) Transaction Indication | · | | | | | | | |
| | | | Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See In | | | that is intended to | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | |

| | 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Transaction Code (Instr. | | | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|---------------------------------|--|---|-----------------------------|---|--------|---------------|-------------------|---|---|---|
| | | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (1150.4) |
| | Common Stock ⁽¹⁾ | 04/15/2024 | | М | | 2,812 | Α | \$ <mark>0</mark> | 43,989 | D | |
| | Common Stock ⁽²⁾ | 04/15/2024 | | F | | 1,427 | D | \$11.89 | 42,562 ⁽³⁾ | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of Deri Sec Acq (A) o Disp of (I | ivative curities vurities vurities or posed D) 0) tr. 3, 4 | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|---|---|--|---|------------------------------|---|--|--|---------------------|--|-----------------|---|--|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Restricted Stock Units | (4) | 04/15/2024 | | М | | | 2,812 | (5) | (5) | Common stock | 2,812 | \$0.00 | 8,439 ⁽⁶⁾ | D | |

Explanation of Responses:

1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.

2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.

3. Represents the common stock remaining after deducting the common stock withheld for taxes.

4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

5. The remaining RSUs will vest in equal quarterly installments.

6. Such aggregate number reflects the remainder of such RSUs granted on January 14, 2022, but does not include any other RSUs held by such Reporting Person.

/s/ Friedrich Graf Finckenstein 04/17/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.